Markets
Stocks
Funds
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Recent Quotes
My Watchlist
Indicators
Gilead Sciences (NQ: GILD)
66.77 USD  -0.86 (-1.27%)
Streaming Delayed Price  /  Updated: 8:22 AM EST, Dec 13, 2019  /  Add to My Watchlist      
View: Quote News Research
Price and Volume
Detailed Quote
Chart for (: )
 
Intraday
1 Week
1 Month
3 Month
1 Year
  
Compare to:
Volume 17,796
Open 67.63
Bid (Size) 66.90 (8)
Ask (Size) 66.98 (1)
Prev. Close 67.63
Today's Range 66.69 - 67.63
52wk Range 60.32 - 70.50
Shares Outstanding 1,300,260,832
Dividend Yield 3.34%
Performance
YTD
+5.25%
+5.25%
1 Month
+3.81%
+3.81%
3 Month
+0.62%
+0.62%
6 Month
-0.33%
-0.33%
1 Year
-2.01%
-2.01%
Top News
More News
Kite and Kiniksa Pharmaceuticals Announce Clinical Collaboration Evaluating Investigational Combination of Yescarta® and Mavrilimumab in Relapsed or Refractory Large B-Cell Lymphoma
Phase 2 study will Examine the Effect of Mavrilimumab on the Clinical Profile of Yescarta Read More
from GlobeNewswire News Releases
Kite Submits Biologics License Application to U.S. Food and Drug Administration for Company’s Second CAR T Cell Therapy
Kite, a Gilead Company (Nasdaq: GILD), today announced that it has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for the investigational chimeric... Read More
from Business Wire News Releases
More News
Read More
Kite and Kiniksa Pharmaceuticals Announce Clinical Collaboration Evaluating Investigational Combination of Yescarta® and Mavrilimumab in Relapsed or Refractory Large B-Cell Lymphoma
from Business Wire News Releases
Kite and the CIBMTR® Present Positive Findings From Real-World Use of Yescarta® (Axicabtagene Ciloleucel) in Relapsed or Refractory Large B-Cell Lymphoma
from Business Wire News Releases
Kite Presents Positive Results From Pivotal ZUMA-2 Trial in Relapsed or Refractory Mantle Cell Lymphoma
from Business Wire News Releases
We Did The Math PJP Can Go To $72
category ETFs
from ETF Channel
Kite Announces Long-term Data From ZUMA-1 Showing Approximately Half of Refractory Large B-cell Lymphoma Patients Were Alive Three Years After Yescarta Treatment
from Business Wire News Releases
Noteworthy Wednesday Option Activity: GILD, GKOS, DERM
category Stocks
from Market News Video
Hot Options Report For End Of Day - Wednesday, Dec. 11
category Options
from Blogs - TalkMarkets
Investors shift attention to next generation of CAR-T, new sickle cell treatments at major hematology meeting
category GBT , GILD , General , and 7 more.
from MarketWatch
No CRISPR Required: This Forgotten Gene Editing is Up 50% in 5 Weeks
category Market News , CRSP , BYND , and 3 more.
from Motley Fool
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Six Financial & Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.